Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan

被引：0
|
作者：
Junji Furuse
Namiki Izumi
Kenta Motomura
Yoshitaka Inaba
Yoshio Katamura
Yasuteru Kondo
Kazuhisa Yabushita
Katsuaki Motoyoshi
Masatoshi Kudo
机构：
[1] Kanagawa Cancer Center,Department of Gastroenterology and Hepatology
[2] Musashino Red Cross Hospital,Department of Hepatology
[3] Aso Iizuka Hospital,Department of Diagnostic and Interventional Radiology
[4] Aichi Cancer Center Hospital,Department of Gastroenterology
[5] Onomichi General Hospital,Department of Hepatology
[6] Sendai Kousei Hospital,Department of Internal Medicine
[7] Fukuyama City Hospital,Department of Gastroenterology and Hepatology
[8] Eisai Co.,undefined
[9] Ltd.,undefined
[10] Kindai University Faculty of Medicine,undefined
来源：
Drugs - Real World Outcomes | 2023年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：195 / 205
页数：10
相关论文
共 50 条
  • [1] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Furuse, Junji
    Izumi, Namiki
    Motomura, Kenta
    Inaba, Yoshitaka
    Katamura, Yoshio
    Kondo, Yasuteru
    Yabushita, Kazuhisa
    Motoyoshi, Katsuaki
    Kudo, Masatoshi
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
  • [2] Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study
    Kang, Wonseok
    Kim, Yoon Jun
    Kim, Seung Up
    Seo, Yeon Seok
    Kim, Jin-Wook
    Kim, Ji Hoon
    Park, Soo Young
    Baek, Yang-Hyun
    Kim, Kang Mo
    Lee, Hae Lim
    Yoon, Ki Tae
    Kim, Hyeyeong
    Cheong, Jae Youn
    Hwang, Jae Seok
    Kim, Ju Hyun
    Kim, Kwang Min
    Sung, Pil Soo
    Kim, Jieun
    Kim, Do Young
    [J]. FUTURE ONCOLOGY, 2024,
  • [3] A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
    Yamazaki, N.
    Kiyohara, Y.
    Sato, M.
    Endo, S.
    Song, B.
    Tanaka, Y.
    Kambe, A.
    Sato, Y.
    Uhara, H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1601 - S1602
  • [4] Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
    Takahashi, Shunji
    Tahara, Makoto
    Ito, Koichi
    Tori, Masayuki
    Kiyota, Naomi
    Yoshida, Katsutoshi
    Sakata, Yukinori
    Yoshida, Akira
    [J]. ADVANCES IN THERAPY, 2020, 37 (09) : 3850 - 3862
  • [5] Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
    Shunji Takahashi
    Makoto Tahara
    Koichi Ito
    Masayuki Tori
    Naomi Kiyota
    Katsutoshi Yoshida
    Yukinori Sakata
    Akira Yoshida
    [J]. Advances in Therapy, 2020, 37 : 3850 - 3862
  • [6] Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
    Kang, W.
    Kim, J.
    Kim, S. U.
    Seo, Y-S.
    Kim, J.
    Kim, J-H.
    Park, S. Y.
    Baek, Y-H.
    Kim, K.
    Lee, H. L.
    Yoon, K. T.
    Kim, H.
    Cheong, J. Y.
    Hwang, J. S.
    Kim, J. H.
    Kim, K. M.
    Sung, P. S.
    Kim, J. J.
    Kim, D-Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S609 - S609
  • [7] Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
    Izumi, N.
    Kudo, M.
    Motomura, K.
    Inaba, Y.
    Katamura, Y.
    Kondo, Y.
    Yabushita, K.
    Motoyoshi, K.
    Furuse, J.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1551 - S1551
  • [8] Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abby
    Davis, Keith L.
    Iyer, Shrividya
    [J]. CANCER REPORTS, 2023, 6 (01)
  • [9] Correction to: Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
    Shunji Takahashi
    Makoto Tahara
    Koichi Ito
    Masayuki Tori
    Naomi Kiyota
    Katsutoshi Yoshida
    Yukinori Sakata
    Akira Yoshida
    [J]. Advances in Therapy, 2021, 38 : 4989 - 4993
  • [10] Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
    Goh, Myung Ji
    Oh, Joo Hyun
    Park, Yewan
    Kim, Jihye
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    [J]. LIVER CANCER, 2021, 10 (01) : 52 - 62
12345